title: Managing diabetic patients with moderate or severe renal impairment using DPP-4 inhibitors: focus on vildagliptin.
abstract: BACKGROUND
  Dipeptidyl peptidase-4 (DPP-4) inhibitors are novel classified oral anti-diabetic drugs for the treatment of type 2 diabetes mellitus (T2DM) that provide important reduction in glycated hemoglobin, with a low risk for hypoglycemia and no weight gain. In T2DM patients with reduced renal function, adequate glycemic control is essential to delay the progress of kidney dysfunction, but they are at a greater risk of experiencing hypoglycemic events, especially with longer-acting sulfonylureas and meglitinides.
  
  
  OBJECTIVE
  To evaluate vildagliptin as an option to achieve glycemic control in T2DM patients with moderate or severe chronic kidney disease (CKD).
  
  
  METHODS
  A comprehensive search in the literature was performed using the term "vildagliptin." Original articles and reviews exploring our topic were carefully selected.
  
  
  RESULTS
  Vildagliptin provides effective glycemic control in patients with T2DM and CKD. Dose reductions are required for vildagliptin and other DPP-4 inhibitors, except linagliptin, in T2DM patients with moderate-to-severe CKD. Dose of vildagliptin had to be reduced by half (to 50 mg/day) both for moderate (estimated glomerular filtration rate [eGFR] ≥30 to ≤50 mL/min) and severe CKD (eGFR < 30 mL/min). Available results support a favorable efficacy, safety, and tolerability profile for vildagliptin in T2DM with moderate or severe renal failure. Preliminary data may suggest additional benefits beyond improvement of glycemic control.
  
  
  CONCLUSIONS
  Vildagliptin can be safely used in T2DM patients with varying degrees of renal impairment. Dose adjustments for renal impairment are required. Potential long-term renal benefit of vildagliptin needs to be further explored.
authors: Department of Clinical and Experimental Medicine, Section of Diabetes and Metabolic Disease, Azienda Ospedaliero Universitaria di Pisa, and University of Pisa, Pisa, Italy.
authors: Eleonora
authors: E
authors: Russo
authors: Giuseppe
authors: G
authors: Penno
authors: Stefano
authors: S
authors: Del Prato
keywords: chronic kidney disease; renal function; type 2 diabetes mellitus
references: JAMA. 2010 Apr 14;303(14):1410-8
references: 20388897
references: Diabetes Care. 2013 Jan;36 Suppl 1:S11-66
references: 23264422
references: Curr Drug Metab. 2011 Jan;12(1):57-69
references: 21303332
references: Diabetes Care. 2011 Jun;34(6):1431-7
references: 21617112
references: Adv Ther. 2012 Jan;29(1):14-25
references: 22215383
references: Am J Pathol. 2013 Jan;182(1):132-41
references: 23159951
references: Intern Med. 2012;51(21):3045-9
references: 23124148
references: Diabetes Obes Metab. 2011 Jan;13(1):55-64
references: 21114604
references: Regul Pept. 2011 Jan 17;166(1-3):48-54
references: 20728477
references: Endocr J. 2011;58(11):979-87
references: 21921362
references: J Clin Pharm Ther. 2012 Aug;37(4):386-98
references: 22191695
references: Diabetes Care. 2013 May;36(5):1067-73
references: 23248197
references: Diabetes Obes Metab. 2010 Jun;12(6):485-94
references: 20518804
references: Drugs. 2011 Jul 30;71(11):1441-67
references: 21812507
references: J Clin Endocrinol Metab. 2012 Oct;97(10):3799-806
references: 22855332
references: Cell Physiol Biochem. 2012;30(3):749-57
references: 22890152
references: Am J Kidney Dis. 2013 Apr;61(4):579-87
references: 23352379
references: Diabetes Care. 2007 Dec;30(12):3017-22
references: 17878242
references: Diabetes Obes Metab. 2012 Nov;14(11):1032-9
references: 22690943
references: Diabetes Obes Metab. 2010 Jun;12(6):495-509
references: 20518805
references: Clin Ther. 2009 Nov;31(11):2608-17
references: 20110005
references: PLoS One. 2012;7(10):e46781
references: 23071636
references: Clin J Am Soc Nephrol. 2009 Jun;4(6):1121-7
references: 19423569
references: Diabetes Obes Metab. 2011 Oct;13(10):947-54
references: 21733061
references: Lancet. 2011 Jul 9;378(9786):182-97
references: 21705062
references: Med J Aust. 2006 Aug 7;185(3):140-4
references: 16893353
references: Arch Med Res. 2009 Oct;40(7):536-44
references: 20082866
references: Diabetes Res Clin Pract. 2010 Nov;90(2):182-90
references: 20655609
references: J Pharmacol Exp Ther. 2012 Feb;340(2):248-55
references: 22025647
references: Diabetes Ther. 2012 Nov;3(1):8
references: 22736406
references: BMJ. 2012 Mar 12;344:e1369
references: 22411919
references: Kidney Int. 2012 Apr;81(7):698-706
references: 22258320
references: Clin Pharmacokinet. 2012 Mar 1;51(3):147-62
references: 22339447
references: Diabetologia. 2011 Aug;54(8):1985-91
references: 21547496
references: Clin Sci (Lond). 2013 Jan;124(1):17-26
references: 22963445
references: Diabetes Obes Metab. 2009 Aug;11(8):804-12
references: 19476473
references: Arch Intern Med. 2011 Nov 28;171(21):1920-7
references: 22123800
references: Kidney Blood Press Res. 2012;36(1):65-84
references: 22947920
references: Expert Opin Pharmacother. 2012 Jun;13(9):1377-84
references: 22397507
references: Diabetes. 2011 Dec;60(12):3103-9
references: 21984584
references: Ann Intern Med. 2011 May 17;154(10):672-9
references: 21576535
references: Am J Kidney Dis. 2002 Feb;39(2 Suppl 1):S1-266
references: 11904577
references: Int J Clin Pract. 2011 Dec;65(12):1230-9
references: 21977965
references: Am J Med. 2011 Jan;124(1 Suppl):S54-61
references: 21194580
references: J Hypertens. 2011 Sep;29(9):1802-9
references: 21738053
references: Diabetes Obes Metab. 2012 May;14(5):454-63
references: 22151893
references: Am J Physiol Renal Physiol. 2012 Sep;303(5):F681-8
references: 22718884